Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Adverum Biotechnologies (ADVM)
NASDAQ:ADVM
RESEARCH TOOLSreports
Holding ADVM?
Track your performance easily
ADVM Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$5.69 - $29.70
Previous Close$6.04
Volume206.59K
Average Volume (3M)209.64K
Market Cap
$125.65M
Enterprise Value$45.67M
Total Cash (Recent Filing)$153.24M
Total Debt (Recent Filing)$73.26M
Price to Earnings (P/E)―
Beta0.94
Next Earnings
Mar 26, 2025EPS Estimate
-$1.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.03
Shares Outstanding20,802,463
10 Day Avg. Volume240,653
30 Day Avg. Volume209,636
Standard Deviation0.27
R-Squared0.04
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)0.89
Price to Sales (P/S)130.02
Price to Cash Flow (P/CF)-1.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue45.67
Enterprise Value/Gross Profit12.69
Enterprise Value/Ebitda-0.52
Forecast
1Y Price Target
$21.00Price Target Upside241.46% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Adverum Biotechnologies News
PremiumCompany Announcements
Adverum Biotechnologies Advances Ixo-vec Gene Therapy Trials
PremiumPre-Earnings
Is ADVM a Buy, Before Earnings?
PremiumCompany Announcements
Adverum Biotechnologies Advances in Gene Therapy Development
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessThe LUNA trial showed an 88% treatment burden reduction for 6E10 dosing and 54% injection freedom, demonstrating robust outcomes for Ixo-vec.
Efficacy And SafetyIxo-vec therapy offers a differentiated wet AMD treatment with significant reduction in treatment burden for hard-to-treat patients.
Market PotentialAnalysts have increased the peak sales estimate for ixo-vec from $1.8 billion to $2.6 billion due to the strong data.
Bears Say
Competitive Pressure4D-150 is the most direct competitor to ADVM's ixo-vec, with a first Phase 3 study expected to begin in 1Q25.
Financial PerformanceThe price target has been adjusted from $20 to $16 due to the assumed cost of the newly disclosed first Phase 3 study and current cash considerations.
Funding ConcernsCash runway to complete the Phase III program remains an overhang.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
ADVM FAQ
What was Adverum Biotechnologies’s price range in the past 12 months?
Adverum Biotechnologies lowest stock price was $5.69 and its highest was $29.70 in the past 12 months.
What is Adverum Biotechnologies’s market cap?
Currently, no data Available
When is Adverum Biotechnologies’s upcoming earnings report date?
Adverum Biotechnologies’s upcoming earnings report date is Mar 26, 2025 which is in 120 days.
How were Adverum Biotechnologies’s earnings last quarter?
Adverum Biotechnologies released its earnings results on Nov 04, 2024. The company reported -$1.3 earnings per share for the quarter, beating the consensus estimate of -$1.307 by $0.007.
Is Adverum Biotechnologies overvalued?
According to Wall Street analysts Adverum Biotechnologies’s price is currently Undervalued.
Does Adverum Biotechnologies pay dividends?
Adverum Biotechnologies does not currently pay dividends.
What is Adverum Biotechnologies’s EPS estimate?
Adverum Biotechnologies’s EPS estimate is -$1.36.
How many shares outstanding does Adverum Biotechnologies have?
Adverum Biotechnologies has 20,802,464 shares outstanding.
What happened to Adverum Biotechnologies’s price movement after its last earnings report?
Adverum Biotechnologies reported an EPS of -$1.3 in its last earnings report, beating expectations of -$1.307. Following the earnings report the stock price went up 2.387%.
Which hedge fund is a major shareholder of Adverum Biotechnologies?
Among the largest hedge funds holding Adverum Biotechnologies’s share is Versant Venture Management, LLC. It holds Adverum Biotechnologies’s shares valued at 4M.
---
Adverum Biotechnologies Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$21.00 (241.46% Upside)
$21.00 (241.46% Upside)
Blogger Sentiment
Bullish
ADVM Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 11.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 5.9%
Last 30 Days ▼ 8.6%
Last 30 Days ▼ 8.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-28.11%
12-Months-Change
Fundamentals
Return on Equity
-76.26%
Trailing 12-Months
Asset Growth
19.11%
Trailing 12-Months
Company Description
Adverum Biotechnologies
Adverum Biotechnologies, Inc. is a clinical-stage biotechnology company that engages in the development of novel gene therapies to treat patients with sight-threatening ophthalmic diseases. It focuses on treatment of wet age-related macular degeneration, alpha-1 antitrypsin deficiency, hereditary angioedema, friedreich's ataxia, severe allergy, color vision deficiency, and juvenile x-linked retinoschisis. The company was founded by Mark S. Blumenkranz, Thomas W. Chalberg, Jr. and Steven Daniel Schwartz on July 17, 2006 and is headquartered in Menlo Park, CA.
---
ADVM Stock 12 Month Forecast
Average Price Target
$21.00
▲(241.46% Upside)
Technical Analysis
Editas Medicine
―
Crispr Therapeutics AG
―
Intellia Therapeutics
―
Meiragtx Holdings
―
Best Analysts Covering ADVM
1 Year
1 Year Success Rate
2/13 ratings generated profit
1 Year Average Return
-33.61%
reiterated a buy rating 7 days ago
Copying Joon Lee's trades and holding each position for 1 Year would result in 15.38% of your transactions generating a profit, with an average return of -33.61% per trade.
---